Vitaspring Biomedical annual free cash flow
2022
2023
Vitaspring Biomedical Free Cash Flow (FCF) History (VSBC)
Vitaspring Biomedical reported −$77,556 in free cash flow for fiscal 2023, an increase of $265,072 from the previous fiscal year.
View full Vitaspring Biomedical company overviewVitaspring Biomedical free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2023 | 2023-01-31 | −$77,556 | $265,072 | — | — |
| 2022 | 2022-01-31 | −$342,628 | — | — | −6.10% |
Vitaspring Biomedical quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Vitaspring Biomedical free cash flow growth trends
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Vitaspring Biomedical filings at SEC.gov ↗